News briefing: Takeda reports PhIII failure for Ninlaro in multiple myeloma; AstraZeneca plots pivot to Nasdaq
Takeda’s plans for Ninlaro have hit a road block.
The pharma giant reported Thursday that its Phase III study adding their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
